| Abingworth Management Limited |
London Genetics Limited |
| Accera, Inc |
LSP |
| Actelion |
LSVenture GmbH |
| Addex Pharmaceuticals Ltd |
Lumavita AG |
| Aderly |
Medical Device Works NV/SA |
| Adveq Management |
MediGene AG |
| Affectis Pharmaceuticals AG |
Merck & Co. |
| Affimed Therapeutics AG |
Merck Serono |
| Agendia |
Merck Serono Ventures |
| ALFAMA, Inc. |
Mergermarket |
| ALRISE Biosystems GmbH |
MolMed S.p.A |
| AM-Pharma B.V. |
Morgan Stanley |
| Apposite Capital LLP |
Nabriva Therapeutics AG |
| Archimedes Pharma Ltd. |
Nature Biotechnology |
| Arpida Ltd. |
Neovacs |
| Axentis Pharma AG |
Nextech Venture |
| Baigo Capital GmbH |
NGN Capital LLC |
| Bank am Bellevue AG |
Nitec Pharma AG |
| Bank Sal. Oppenheim jr. & Cie. (Switzerland) Ltd. |
NOLabs AB |
| Bank Sarasin & Cie AG |
Nomura Code Securities |
| Bank Vontobel AG |
Nomura Phase4 Ventures |
| Basler Zeitung |
Novartis International AG |
| Bavarian Nordic A/S |
Novartis Pharma AG |
| Bellevue Asset Management |
Novartis Vaccines & Diagnostics |
| BioCeramic Therepeutics |
Novartis Venture Funds |
| Biocrates Life Sciences GmbH |
Novo A/S |
| BioMedPartners |
NOXXON Pharma AG |
| Biotie Therapies Corp. |
Nycomed International Management GmbH |
| Bloomberg News |
Paul Capital Partners |
| Breslin AG |
Peppermint Management GmbH & Charité Biomedical Fund |
| Bridgehead International |
peptides&elephants GmbH |
| BRUCELLS s.a |
PH Regulatory Medical Advisors |
| Capstone Therapeutics |
Pharmaceutical Partnering Specialist |
| Cayla Consulting Group |
PharmaNeuroBoost NV |
| Cederberg Advisors |
PharmaVentures Ltd. |
| Celonic AG |
PharmaWave Ltd |
| CFP BioConnect AG |
Phylogica |
| Clinuvel AG |
PolyMedix Inc. |
| College Hill |
PricewaterhouseCoopers |
| Cosmo Pharmaceuticals S.p.A. |
ProtAffin Biotechnologie AG |
| Credit Suisse |
Quest Management NV |
| CuraVac |
Revotar Biopharmaceuticals AG |
| Cytos AG |
Roche Venture Fund |
| Deloitte AG |
Rothschild |
| Deutsche Bank AG |
Sachs Associates Ltd |
| Diamyd Medical AB |
Sal. Oppenheim Jr. & Cie |
| DyoDelta Biosciences |
Savira Pharmaceuticals |
| Earlybird Venture Capital |
Scancell Limited |
| Edmond de Rothschild Investment Partners |
Scottish Equity Partners |
| Emotional Brain bv |
SGS Institut Fresenius GmbH |
| Endeavour Vision SA |
Sigma-Tau Pharma Ltd. |
| Endosense |
Silence Therapeutics AG |
| Epistem Ltd. |
Sirius Healthcare Partners |
| Equity Development Ltd. |
SIX Swiss Exchange AG |
| Excellentia Global Partners |
Sofinnova Partners |
| F. Hoffmann-La Roche Ltd |
Symphogen A/S |
| Ferghana Partners |
Teva Pharmaceutical Industries LTD. |
| Forbion Capital Partners |
The Visium Funds |
| Galantos Pharma GmbH |
TiGenix NV |
| Gilde Healthcare Partners |
to-BBB technologies BV |
| GlaxoSmithKline |
Trigon Medical AG |
| Global Life Science Ventures |
TVM Capital |
| Global Life Science Ventures |
UBS Global Asset Management |
| Glycotope GmbH |
Uniobioscreen SA |
| Grace Advisory |
Ventech |
| HBM Partners AG |
Venture Valuation AG |
| Helsinn Healthcare SA |
Versant Ventures |
| immatics biotechnologies GmbH |
Vesalius Biocapital |
| Immune Targeting Systems Ltd |
Vetter Pharma-Fertigung GmbH & Co. KG |
| Imperial Innovations Limited |
Warburg Pincus LLC |
| Innate Pharma SAS |
Wellcome Trust |
| International Bioscience Managers Ltd |
Wellington Partners |
| INVEST SECURITIES |
Werder Consulting |
| J P Morgan Investment Management Inc |
Widmann Associates |
| Jefferies International |
Wilex AG |
| Johnson & Johnson Pharmaceuticals Group |
Yissum Research Development Company of the Hebrew University of Jerusalem |
| Katan Associates |
Zürcher Kantonalbank |
| Kenta Biotech AG |
|